Get the Stockscreener App
1.58
3.27%
0.05
Cardiol Therapeutics Inc stock is traded at $1.58, with a volume of 310.41K.
It is up +3.27% in the last 24 hours and down -17.71% over the past month.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.
See More
Previous Close:
$1.53
Open:
$1.53
24h Volume:
310.41K
Relative Volume:
0.65
Market Cap:
$126.08M
Revenue:
-
Net Income/Loss:
$-21.65M
P/E Ratio:
-4.5001
EPS:
-0.3511
Net Cash Flow:
$-15.84M
1W Performance:
+1.28%
1M Performance:
-17.71%
6M Performance:
-32.77%
1Y Performance:
+77.55%
1-Day Range:
$1.49
$1.60
1-Week Range:
$1.49
$1.655
52-Week Range:
$0.7912
$3.12
Cardiol Therapeutics Inc Stock (CRDL) Company Profile
Compare CRDL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRDL
Cardiol Therapeutics Inc
|
1.58 | 126.08M | 0 | -21.65M | -15.84M | -0.3511 |
|
ZTS
Zoetis Inc
|
176.74 | 80.59B | 9.15B | 2.43B | 2.31B | 4.92 |
|
HLN
Haleon Plc Adr
|
9.72 | 44.17B | 14.26B | 1.55B | 0 | 0.3327 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.57 | 42.61B | 30.27B | 1.93B | 3.45B | 0.444 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.57 | 18.77B | 16.77B | -959.00M | 1.37B | -2.00 |
|
VTRS
Viatris Inc
|
13.22 | 15.73B | 15.05B | -883.30M | 1.89B | 1.53 |
Cardiol Therapeutics Inc Stock (CRDL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-26-24 | Initiated | ROTH MKM | Buy |
| Apr-22-24 | Initiated | H.C. Wainwright | Buy |
Cardiol Therapeutics Inc Stock (CRDL) Latest News
Cardiol Therapeutics (FRA:CT9) Cyclically Adjusted Revenue per Share : €0.00 (As of Sep. 2024) - GuruFocus.com
Game-Changing Solution for Heart Inflammation? | David Elsley – Cardiol Therapeutics - The Deep Dive
HC Wainwright Issues Optimistic Estimate for CRDL Earnings - Defense World
Comparing Cardiol Therapeutics (NASDAQ:CRDL) & Gilead Sciences (NASDAQ:GILD) - Defense World
What is HC Wainwright's Forecast for CRDL FY2024 Earnings? - MarketBeat
Equities Analysts Set Expectations for CRDL FY2024 Earnings - Defense World
Cardiol Therapeutics (NASDAQ:CRDL) Earns Buy Rating from HC Wainwright - Defense World
Cardiol Therapeutics (TSE:CRDL) Shares Up 1.8%What's Next? - MarketBeat
Leede Financial Issues Positive Forecast for CRDL Earnings - Defense World
Cardiol Therapeutics (Nasdaq: CRDL) Advances Orphan Drug - openPR
What is Leede Financial’s Estimate for CRDL FY2027 Earnings? - Defense World
What is Leede Financial's Forecast for CRDL FY2024 Earnings? - MarketBeat
Roth Capital Has Negative Outlook for CRDL FY2024 Earnings - MarketBeat
Biotech Initiates Phase III Trial for Heart Disease Drug - Streetwise Reports
Pericarditis Drugs Market Is Expected To Reach $816.6 Million - openPR
Cardiol Therapeutics (NASDAQ:CRDL) Given Buy Rating at HC Wainwright - MarketBeat
What is Leede Financial's Forecast for CRDL FY2027 Earnings? - MarketBeat
CBD-Based Drug Reduces Pericarditis Pain And Inflammation, Shows New Clinical Study - Benzinga
Analyst Says Biotech's Data Supports Advancement Into Phase III - Streetwise Reports
Five Top Heart Health Stocks to Buy Heading into 2025 - Baystreet.ca
Spotlight on Undervalued Nasdaq Stocks: HCWB, CRDL, NIVF, SINT, APLMA Must-Watch This Week! - openPR
Cardiol Therapeutics Inc. - Baystreet.ca
Cardiol Therapeutics reports promising Phase II results for recurrent pericarditis therapy - Proactive Investors USA
Palantir Technologies Inc Cl A (PLTR-N) QuotePress Release - The Globe and Mail
Cardiol's CardiolRx Shows Major Pain Relief Success in Phase II Pericarditis Trial | CRDL Stock News - StockTitan
Cardiol Therapeutics Faces Rising Losses and Falling Assets - TipRanks
Wealth Enhancement Advisory Services LLC Takes $27,000 Position in Cardiol Therapeutics Inc. (NASDAQ:CRDL) - Defense World
"Emerging Innovators Transforming Global Markets: IPA, CRDL, KXIN, GNS, PRSO in Sectors" - WICZ
“Emerging Innovators Transforming Global Markets: IPA, CRDL, KXIN, GNS, PRSO in Sectors” - The Globe and Mail
Cardiol Therapeutics Inc. Added to PRISM Emerging Biotech Index - Investing News Network
Cardiol Therapeutics (OTCMKTS:CRTPF) Stock Price Down 3.9% – Here’s What Happened - Defense World
Amazon.com Inc (AMZN-Q) QuotePress Release - The Globe and Mail
Biotech and Technology Giants Drive Innovation Across Pharma, Medical Devices, and Industrial Automation CRDL, MODD, CYN - The Globe and Mail
Biotech and Technology Giants Drive Innovation Across Pharma, Me - WICZ
Cardiol Therapeutics (TSX:CRDL) Shares Outstanding (EOP) : 69.32 Mil (As of Jun. 2024) - GuruFocus.com
MMCAP International Inc. SPC Acquires Shares in Cardiol Therapeu - GuruFocus.com
Comparing Cardiol Therapeutics (NASDAQ:CRDL) and IN8bio (NASDAQ:INAB) - Defense World
Net Present Value Model: Cardiol Therapeutics Inc’s Cannabidiol 1 - GlobalData
Top 4 Canadian Biotech Stocks of 2024 - Investing News Network
Cardiol Therapeutics (TSE:CRDL) Shares Down 0.8% – Should You Sell? - Defense World
Cardiol Therapeutics (TSE:CRDL) Trading Down 0.8%Should You Sell? - MarketBeat
Cardiol Therapeutics Inc. (NASDAQ:CRDL) Sees Large Increase in Short Interest - MarketBeat
“Top Biotech Opportunities: RVNC, HCTI, GLUE, PRSO, CRDL, Showing Promising Developments” - The Globe and Mail
HC Wainwright Issues Negative Outlook for CRDL Earnings - Defense World
Equities Analysts Set Expectations for CRDL Q3 Earnings - MarketBeat
Cardiol Therapeutics Inc. (NASDAQ:CRDL) Shares Acquired by Foundations Investment Advisors LLC - Defense World
HC Wainwright Reiterates "Buy" Rating for Cardiol Therapeutics (NASDAQ:CRDL) - MarketBeat
H.C. Wainwright maintains Buy rating on Cardiol Therapeutics shares By Investing.com - Investing.com UK
Are Medical Stocks Lagging Cardiol Therapeutics (CRDL) This Year? - MSN
Cardiol Therapeutics advances CardiolRx in new trial By Investing.com - Investing.com Australia
Healthcare and Biotech Stocks to Watch: MODD, CRDL, DBVT, VRAX - openPR
Cardiol Therapeutics Inc Stock (CRDL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.83%
1.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):